- Home
- RVNC
as 11-07-2024 4:00pm EST
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NASHVILLE |
| Market Cap: | 599.6M | IPO Year: | 2014 |
| Target Price: | $10.86 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.30 - $9.75 | Next Earning Date: | 11-19-2024 |
| Revenue: | $251,178,000 | Revenue Growth: | 40.23% |
| Revenue Growth (this year): | 20.36% | Revenue Growth (next year): | 31.66% |
Latest Revance Therapeutics Inc. News
RVNC Breaking Stock News: Dive into RVNC Ticker-Specific Updates for Smart Investing
MT Newswires
21 days ago
Revance Therapeutics, Crown Laboratories Extend Merger Date Amid Commercialization Dispute
Zacks
a month ago
Down -17.96% in 4 Weeks, Here's Why Revance Therapeutics (RVNC) Looks Ripe for a Turnaround
MT Newswires
2 months ago
Top Premarket Decliners
GuruFocus.com
2 months ago
Beryl Capital Management LLC Acquires New Stake in Revance Therapeutics Inc
MT Newswires
2 months ago
Barclays Downgrades Revance Therapeutics to Equalweight From Overweight, Price Target is $7
GuruFocus.com
2 months ago
Capital World Investors Reduces Stake in Revance Therapeutics
Zacks
2 months ago
How Much Upside is Left in Revance Therapeutics (RVNC)? Wall Street Analysts Think 55.02%
Zacks
3 months ago
Can Revance Therapeutics (RVNC) Climb 98.64% to Reach the Level Wall Street Analysts Expect?
Compare RVNC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RVNC Revance Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.